A Candidate Dengue Vaccine - Current Status
Main Article Content
Abstract
The most advanced candidate vaccine against dengue viruses, called CYD-TDV, is progressing toward potential registration and reviewed by the World Health Organization (WHO) in 2016. CYD-TDV is a tetravalent, live attenuated, chimeric dengue vaccine in a Yellow fever 17D back bone developed by Sanofi Pasteur. The schedule that has been evaluated in phase III clinical trials included 3 doses of vaccine (at 0, 6 and 12 months).
Article Details
How to Cite
1.
M Akhtarul Islam. A Candidate Dengue Vaccine - Current Status. TAJ. 2015;28(1):i-ii. doi:10.70818/taj.2015.v028i01.044
Section
Editorial
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
M Akhtarul Islam. A Candidate Dengue Vaccine - Current Status. TAJ. 2015;28(1):i-ii. doi:10.70818/taj.2015.v028i01.044